Antimicrobial peptides are highly conserved immune effectors across the tree of life and 31 are employed as combinations. In the beetle Tenebrio molitor, a defensin and a 32 coleoptericin are highly expressed in vivo after inoculation with S. aureus. The defensin 33 displays strong in vitro activity but no survival benefit in vivo. The coleoptericin 34 provides a survival benefit in vivo, but no activity in vitro. To investigate this paradox we 35 experimentally evolved S. aureus to increased resistance against the defensin and a 36 combination of the defensin and coleoptericin. Genome re-sequencing showed that 37 resistance was associated with mutations in either the ytr or nsa operons, in both AMP 38 treatments. Strains with these mutations show longer lag phases, slower Vmax and nsa 39 mutants reach lower final population sizes. Mutations in rpoB were showed a further 40 increase in the lag phase in nsa mutants but not in ytr mutants. In contrast, final MICs do 41 not segregate by mutation. All resistant lines display AMP but not antibiotic cross-42 resistance. Costly resistance against AMPs readily evolves for an individual AMP as well 43 as a naturally occurring combination in vitro and provides broad protection against 44 AMPs. Such non-specific resistance could result in strong selection on host immune 45 systems that rely on cocktails of AMPs. 46 47 48
In a recent experimental evolution study investigating S. aureus resistance evolution 71 against three different AMPs from different organisms (melittin, pexiganan and iseganan 72 11 ), we found a range of mutations associated with resistance 12 . These mutations did not 73 segregate by AMP. 74 75 4 An interesting observation is that during an infection antimicrobial peptides are 76 expressed that have no known activity against the agent of infection. This is surprising, 77 given that insects for example have different receptors that can distinguish between 78 classes of infectious microbes such as fungi or bacteria 13 and energetic costs of protein 79 synthesis are considered to be high 3 . Moreover, recent studies, for example in bumble 80 bees, have also shown pathogen strain specific responses on the level of the 81 transcriptome 14 . In the mealworm beetle Tenebrio molitor experimental infection with 82 S. aureus induces the expression of at least ten antimicrobial peptides for a week 3 . A 83 proteomic analysis shows that the majority of these inducible antimicrobial peptides 84 remain elevated in the haemolymph after three weeks 15 AMPs) readily evolved a high level of resistance. All lines were able to grow in the 241 presence of 256 µg/ml Tenecin 1 and 512 µg/ml Tenecin 2 , resulting in an increase in 242 MIC for Tenecin 1 (T=-9.98, df=35, p=<0.0001, Fig. 1A ).
244
Reduced fitness in AMP-resistant mutants
245
When comparing bacterial growth curves of the mutants with those of non-selected 246 controls and ancestors, we found consistently slower growth rates in the exponential 247 phase for both Tenecin 1 (T = -6.8, df = 56, p = <0.0001, Fig. 1B) and Tenecin 1+Tenecin 248 2-selected lines (T = -7.17, df = 56, p = <0.0001, Fig. 1B ) and also extended lag phases 249 (Tenecin 1: T = 9.4, df = 56, p = <0.0001, Tenecin 1+Tenecin 2: T = 9.1, df = 56, p = 250 <0.0001, Fig. 1B) , Tenecin 1 and Tenecin 1+Tenecin 2 lines did not differ (T = -0.67, df = 251 56, p = 0.5042, Fig. 1AB ). This suggests that AMP resistance incurs fitness costs 252 irrespective of the type of selection.
254
Cross-Resistance to other AMPs but not antibiotics
255
We tested for cross-resistance against commercially available AMPs, colistin, pexiganan 256 and melittin. We found 2-8-fold cross-resistance of all AMP-selected strains against the 257 AMPs Mellitin, Pexiganan and Colistin (table S1). The selected strains showed no cross-258 resistance against Vancomycin, a drug of last resort for staphylococcal infections with 259 multiple resistances. There was no relationship between the AMP cross-resistance and 260 the resistance mutations (see table S2 ). We also tested the evolved strains against a 261 panel of eight antibiotics (see table S2 ) but detected no cross-resistance.
263 11
Genome re-sequencing reveals mutations in a limited number of loci
264
Whole genome sequencing of the selected mutants and the respective controls (at the 265 population and single colony levels) showed differences both between treatments and 266 between replicate lines within treatments. In each resistant strain one mutation was 267 identified in either ytrA, ytrB, nsaS, or nsaR gene, all of which are known to be involved 268 in envelope stress tolerance (see also 
278
Reduced fitness in relation to resistance mutations.
280
Fitness reduction, as measured by the increased lag phase, did not segregate by 281 mutation (T = 0.93, df = 56, p = 0.3576, Fig. 3A ). Vmax differed between nsa and ytr 282 mutations, with nsa mutants showing a lower growth rate than ytr mutants (T = 2.7, df = 283 56, p = 0.0092) and both mutants grow significantly slower than the controls (ytr: T = -284 6.46, df = 56, p = <0.0001, nsa: T = -8.16, df = 56, p = <0.0001, Fig.3B ). In the presence of 285 a second mutation rpo, nsa mutants show a further extension of the lag phase (T = 4.21, 286 df = 54, p = 1e-04, Fig.3B ). Using the Jaccard distance to calculate the degree of parallel evolution, we did not find 294 evidence for parallel evolution at the operon level. Selection treatment (T1 or T1T2) did 295 not affect the mean proportion of shared mutated operons (permutational analysis of 296 multivariate homogeneity of group dispersion F = 0.1925, p = 0.625) or the mean 297 number of shared mutations (permutational multivariate analysis of Jaccard distance 298 matrix, F = 1.063, p = 0.347, Fig. 4 ). Yet, as reported above, all AMP selected lines 299 showed either a mutation in nsa or in ytr operons, but never in both (table 2) .
301
Discussion 302
Our study was one of the first to explore the evolution of resistance to AMPs that are 303 part of the same immune system. We find that all populations under antimicrobial 304 peptide selection evolve resistance quickly and to a similar degree irrespective of the 305 presence of one or two AMPs. In all cases resistant strains possessed a mutation in 306 either in the ytr or nsa operons. Mutations in these operons were not found together.
307
We have previously shown that evolution of resistance towards the AMP melittin in S.
308
aureus JLA513 is associated with nonsense mutations in ytrA. Here we find that the most 309 frequent ytrA mutation is identical to the stop-gain mutation described in 
